Advertisement
Canada markets close in 4 hours 18 minutes
  • S&P/TSX

    21,810.40
    -63.32 (-0.29%)
     
  • S&P 500

    5,012.74
    -58.89 (-1.16%)
     
  • DOW

    37,878.28
    -582.64 (-1.51%)
     
  • CAD/USD

    0.7302
    +0.0005 (+0.06%)
     
  • CRUDE OIL

    82.26
    -0.55 (-0.66%)
     
  • Bitcoin CAD

    87,418.48
    -1,346.91 (-1.52%)
     
  • CMC Crypto 200

    1,376.35
    -6.22 (-0.45%)
     
  • GOLD FUTURES

    2,346.50
    +8.10 (+0.35%)
     
  • RUSSELL 2000

    1,967.38
    -28.05 (-1.41%)
     
  • 10-Yr Bond

    4.7000
    +0.0480 (+1.03%)
     
  • NASDAQ

    15,460.23
    -252.52 (-1.61%)
     
  • VOLATILITY

    16.86
    +0.89 (+5.57%)
     
  • FTSE

    8,075.40
    +35.02 (+0.44%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • CAD/EUR

    0.6810
    -0.0009 (-0.13%)
     

How Analysts Are Rating Puma Biotechnology in July

How Analysts Are Rating Puma Biotechnology in July

The positive recommendation from CHMP comes after a reexamination of negative recommendations at the meeting for the MAA on February 23. On July 5, the company had a consensus 12-month target price of $94.17, which represents a 60.29% return on investment over the next 12 months. On July 5, Incyte had a consensus 12-month target price of $83.71, which represents an 18.65% return on investment over the next 12 months.